Prime Medicine, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Prime Medicine, Inc. (PRME) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 3.20 million shares for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-03-03
- Prime Medicine, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2024 was 3.20M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|
| 2024-12-31 | 3.20M shares 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |